PL3507303T3 - Przeciwciała CD20 - Google Patents

Przeciwciała CD20

Info

Publication number
PL3507303T3
PL3507303T3 PL17762244.6T PL17762244T PL3507303T3 PL 3507303 T3 PL3507303 T3 PL 3507303T3 PL 17762244 T PL17762244 T PL 17762244T PL 3507303 T3 PL3507303 T3 PL 3507303T3
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL17762244.6T
Other languages
English (en)
Inventor
Jeannette Henrica Wilhelmina LEUSEN
Peter Boross
Johannes Hendrik Marco Jansen
Saskia MEYER
Original Assignee
Tigatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigatx, Inc. filed Critical Tigatx, Inc.
Publication of PL3507303T3 publication Critical patent/PL3507303T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734Complement-dependent cytotoxicity [CDC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL17762244.6T 2016-09-01 2017-09-01 Przeciwciała CD20 PL3507303T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16186850 2016-09-01
PCT/NL2017/050581 WO2018044172A1 (en) 2016-09-01 2017-09-01 Cd20 antibodies

Publications (1)

Publication Number Publication Date
PL3507303T3 true PL3507303T3 (pl) 2025-12-08

Family

ID=56852201

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17762244.6T PL3507303T3 (pl) 2016-09-01 2017-09-01 Przeciwciała CD20

Country Status (10)

Country Link
US (2) US11414495B2 (pl)
EP (1) EP3507303B1 (pl)
JP (1) JP2019530661A (pl)
CN (1) CN109843925A (pl)
AU (1) AU2017320457A1 (pl)
CA (1) CA3035427A1 (pl)
ES (1) ES3049907T3 (pl)
HU (1) HUE073389T2 (pl)
PL (1) PL3507303T3 (pl)
WO (1) WO2018044172A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113260632A (zh) * 2018-10-29 2021-08-13 蒂嘉特克斯公司 包含IgA抗体构建体的组合物和方法
CN114096559B (zh) 2019-03-27 2026-03-20 蒂嘉特克斯公司 工程化iga抗体及其使用方法
AU2020351205A1 (en) * 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
IL302412A (en) 2020-11-06 2023-06-01 Novartis Ag Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
CN1802388B (zh) * 2003-05-09 2011-01-05 杜克大学 Cd20特异抗体及使用它们的方法

Also Published As

Publication number Publication date
EP3507303B1 (en) 2025-07-23
EP3507303C0 (en) 2025-07-23
CN109843925A (zh) 2019-06-04
HUE073389T2 (hu) 2026-01-28
ES3049907T3 (en) 2025-12-18
AU2017320457A1 (en) 2019-03-28
WO2018044172A1 (en) 2018-03-08
US20230022731A1 (en) 2023-01-26
EP3507303A1 (en) 2019-07-10
JP2019530661A (ja) 2019-10-24
CA3035427A1 (en) 2018-03-08
WO2018044172A8 (en) 2019-03-21
US20190263922A1 (en) 2019-08-29
US11414495B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
ZA201900353B (en) Anti-pd-l1 antibodies
ZA201900373B (en) Anti-tim-3 antibodies
IL262295A (en) Antibodies against pd-l1
HUS2500024I1 (hu) ANTI-PD-1 ellenanyagok
ZA201803874B (en) Humanized anti-cd73 antibodies
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
PL3512547T3 (pl) Przeciwciała anty-pd-1
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
SG10201603721TA (en) Anti-CTLA-4 Antibodies
SG11201705552QA (en) Anti-pd-l1 antibodies
ZA201807167B (en) Humanized anti-il-1r3 antibodies
GB201610044D0 (en) Antibodies
IL256579A (en) Human antibodies
GB201616699D0 (en) Antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201603291D0 (en) Antibodies
PT3484921T (pt) Anticorpos anti-il-22r
PL3371216T3 (pl) Humanizowane przeciwciała anty-BAG3
IL260083B1 (en) Antibody against myl9
HUE073389T2 (hu) CD20 antitestek
GB201511196D0 (en) Monoclonal antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies